Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Akari Therapeutics PLC (AKTX) had Return on Tangible Equity of 4370.30% for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-10.01M |
|
-- |
|
-- |
|
$16.81M |
|
$-16.81M |
|
$6.80M |
|
$-10.01M |
|
$-10.01M |
|
$-10.01M |
|
$-10.01M |
|
$-10.01M |
|
$-10.01M |
|
$-16.81M |
|
$-16.80M |
|
4.89M |
|
4.89M |
|
$-2.04 |
|
$-2.04 |
|
| Balance Sheet Financials | |
$4.34M |
|
-- |
|
$0.01M |
|
$4.36M |
|
$4.58M |
|
-- |
|
-- |
|
$4.58M |
|
$-0.23M |
|
$-0.23M |
|
$-0.23M |
|
6.62M |
|
| Cash Flow Statement Financials | |
$-16.43M |
|
-- |
|
$7.02M |
|
$13.25M |
|
$3.85M |
|
$-9.40M |
|
$1.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.43M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
4370.38% |
|
|
Return on Tangible Equity |
4370.30% |
-229.80% |
|
4370.31% |
|
$-0.03 |
|
$-3.36 |
|
$-3.36 |
|